DHR
Danaher Corp.
Is DHR Halal?
Life-science, diagnostics and environmental tools are generally permissible, subject to product review.
What You Should Know
Danaher's March 27, 2026 filing shows debt/assets of 22.12%, liquidity/assets of 6.82%, receivables plus cash/assets of 11.40% and disclosed interest income/revenue of 0.45%. Its life-science, diagnostics, biotechnology and environmental businesses generally support health and research, while ingredients, animal research, biopharma workflows and acquisition exposures require qualitative review.
⚠️ Concerns
- •Product ingredients, laboratory workflows and animal research require scholarly and ethical review
- •Biopharma and diagnostics revenue is not allocated by a universal prohibited-activity taxonomy
- •Pending acquisitions and integration debt can change the activity and financial profile
- •Financial ratios pass the examined asset-based screens, but business classification remains incomplete
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-27; calculated 2026-07-14.
18,484 / 83,544
5,701 / 83,544
9,520 / 83,544
27 / 5,951
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 22.12%, liquidity/assets is 6.82%, receivables plus cash/assets is 11.40% and interest income/revenue is 0.45%, below the examined limits; activity classification remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 22.12%, liquidity/assets is 6.82% and receivables plus cash/assets is 11.40%, below the examined MSCI total-assets limits; activity classification remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
The examined ratios pass at debt/assets 22.12% and liquidity/assets 6.82%; activity classification remains incomplete and this is not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A licensed historical market-cap series is not stored and activity classification remains incomplete, so market-cap methods are not estimated from a current spot price.
Business-activity disclosure
Danaher develops and supplies life-science instruments, diagnostics, biotechnology tools and environmental solutions. These activities generally support health, research and environmental protection, while product-specific diagnostics, biopharma, animal research and the pending Masimo acquisition require continuing qualitative review.
Limitation: The filing does not allocate revenue by product ingredient, research method, animal-testing exposure, customer end use or other universal prohibited-activity taxonomy.
Purification
Danaher discloses $27 million of interest income but does not prescribe a scholar-approved purification percentage; the 0.45% ratio is evidence for the income screen, not a complete purification prescription.
Inputs, assumptions and primary sources
- Amounts are USD millions from Danaher's March 27, 2026 Form 10-Q and rounded to the nearest million.
- Debt includes $923 million of current notes payable/current long-term debt and $17,561 million of long-term debt; operating leases are excluded.
- Cash and cash equivalents are $5,701 million; no separately identified interest-bearing securities balance is added.
- First-quarter sales are $5,951 million, receivables are $3,819 million and disclosed interest income is $27 million.
- Danaher's fiscal quarter ended March 27, 2026 rather than calendar quarter-end.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →